Loading...
•
Dec 31, 2022
McKesson Q3 2023 Earnings Report
McKesson reported solid Q3 2023 results, driven by execution across scaled distribution businesses and differentiated capabilities in oncology and biopharma services platforms. The company raised its full-year guidance.
Key Takeaways
McKesson Corporation reported a 3% increase in total revenues to $70.5 billion for the third quarter of fiscal year 2023. Earnings per diluted share from continuing operations increased by $7.69 to $7.65, while Adjusted Earnings per Diluted Share increased by 12% to $6.90. The company also raised its fiscal 2023 Adjusted Earnings per Diluted Share guidance to a range of $25.75 to $26.15.
Total revenues increased 3% to $70.5 billion.
Earnings per diluted share from continuing operations increased $7.69 to $7.65.
Adjusted Earnings per Diluted Share increased 12% to $6.90.
Fiscal 2023 Adjusted Earnings per Diluted Share guidance raised to $25.75 to $26.15.
McKesson
McKesson
McKesson Revenue by Segment
Revenue by Segment
U.S. Pharmaceutical Revenue
CapyFin.comPrescription Technology Solutions Revenue
CapyFin.comMedical-Surgical Solutions Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
McKesson raised fiscal 2023 Adjusted Earnings per Diluted Share guidance to $25.75 to $26.15 from the previous range of $24.45 to $24.95 to reflect solid operating business performance.
Positive Outlook
- U.S. government’s COVID-19 vaccine distribution program: $0.70 to $0.80
- U.S. government’s kitting, storage, and distribution of ancillary supplies program and COVID-19 tests: $1.10 to $1.20
- Approximately ($0.15) related to year-to-date net gains and losses associated with McKesson Ventures’ equity investments
- $0.65 related to the termination of the tax receivable agreement with Change Healthcare
- Fiscal 2023 Adjusted Earnings per Diluted Share Excluding Certain Items guidance indicates 13% to 16% forecasted growth compared to prior year.
Revenue & Expenses
Visualization of income flow from segment revenue to net income